Investor discloses 14.1% Neuronetics stake
Jorey Chernett filed a Schedule 13D reporting a large stake in Neuronetics, Inc. He beneficially owns 9,778,718 shares of common stock, representing about 14.12% of the 69,276,593 shares outstanding as of March 10, 2026.
Rhea-AI Filing Summary
Jorey Chernett filed a Schedule 13D reporting a large stake in Neuronetics, Inc. He beneficially owns 9,778,718 shares of common stock, representing about 14.12% of the 69,276,593 shares outstanding as of March 10, 2026.
The shares were acquired in private transactions using personal funds totaling $19,557,436. Chernett holds sole voting and dispositive power over all reported shares and describes himself as a private investor who believed the stock was undervalued when purchased. He currently has no specific plans for corporate actions but may buy or sell more shares and may engage with management, the board, and other stockholders about strategy, capital structure, governance, or potential business combinations.
Positive
- None.
Negative
- None.
Insights
Private investor discloses a 14.12% Neuronetics stake, signaling potential future engagement.
Jorey Chernett now beneficially owns 9,778,718 Neuronetics shares, or about 14.12% of the company, acquired for $19,557,436 through private transactions. That size makes him a significant shareholder with sole voting and dispositive power over the stake.
The filing states he bought the shares believing they were undervalued and that he has no present concrete plans for corporate actions tied to specific restructuring, transactions, or governance changes. However, the disclosure lists a wide range of possible future steps, from buying or selling more stock to discussing strategy, capitalization, board composition, or potential business combinations.
This language is typical of an investor keeping options open rather than committing to a defined campaign. The impact for other shareholders will depend on whether he later pursues actions like board changes or transaction proposals, which would be reflected in subsequent filings and company communications.
Key Figures
Key Terms
Schedule 13D regulatory
beneficially owned financial
sole voting power financial
sole dispositive power financial
private transactions financial
contracts, arrangements, understandings or relationships regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake did Jorey Chernett report in Neuronetics (STIM)?
Why did Jorey Chernett file a Schedule 13D for Neuronetics (STIM)?
What future actions does Jorey Chernett contemplate regarding Neuronetics (STIM)?
AI-generated analysis. How Rhea-AI works. Not financial advice.